13.08.2026 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) reported sales of €149.3 million in the first half of 2026. The group’s adjusted EBIT dropped by just under 6% to €33.3 million. Adjusted EBIT in the Medical segment rose by nearly 7% to €24.9 million. Net income grew by approximately 5% to €22.4 million, or €0.36 per share. Adjusted for the extraordinary licensing revenue in the same period of the previous year, group sales increased by 4% and earnings by as much as 9%. The licensing business had not yet generated revenues in 2026.

In the Medical segment, sales in the first half of the year totaled €80.9 million, slightly above the prior-year level (€80.5 million). The pharmaceutical radioisotopes business remains the most important revenue driver. The Isotope Products segment generated sales of €68.5 million, which were nearly unchanged compared with the prior year.

For the current fiscal year 2026, the Executive Board confirms its profit forecast published on
26 March 2026, with sales of around €320 million and an adjusted EBIT of around €80 million.

The complete quarterly report can be viewed here: https://www.ezag.com/Q22026en

2nd Quarter 2026:

• Sales: €76.4 million (PY: €80.6million)
• EBIT before special items: €17.4 million (PY: €19.2 million)
• Net income: €12.1 million (PY: €11.8 million)

1st Half Year 2026:

• Sales: €149.3 million (PY: €148.8 million)
• EBIT before special items: €33.3 million (PY: €35.4 million)
• Net income: €22.4 million (PY: €21.4 million)

Forecast 2026:

• Sales of around €320 million (confirmed)
• EBIT before special items of around €80 million (confirmed)

Source :Press Release Eckert & Ziegler
Eckert & Ziegler im ersten Halbjahr 2026 auf Kurs